Brokerages Set Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) PT at $15.40

Share on StockTwits

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has been given an average recommendation of “Buy” by the seven analysts that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $15.40.

A number of equities research analysts have recently weighed in on FOMX shares. Zacks Investment Research upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd. Cowen set a $30.00 price target on Foamix Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price target (up previously from $10.00) on shares of Foamix Pharmaceuticals in a research note on Monday, October 21st.

FOMX opened at $2.79 on Tuesday. The business’s 50-day moving average is $3.31 and its two-hundred day moving average is $2.90. Foamix Pharmaceuticals has a 1 year low of $1.97 and a 1 year high of $4.48. The company has a current ratio of 5.72, a quick ratio of 5.72 and a debt-to-equity ratio of 0.24.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its earnings results on Monday, November 11th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.07). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 100.58%. As a group, research analysts anticipate that Foamix Pharmaceuticals will post -1.66 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its stake in shares of Foamix Pharmaceuticals by 76.5% during the second quarter. Royal Bank of Canada now owns 13,694 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 5,937 shares during the last quarter. grace capital grew its stake in shares of Foamix Pharmaceuticals by 86.9% during the second quarter. grace capital now owns 20,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 9,300 shares during the last quarter. Worth Venture Partners LLC grew its stake in shares of Foamix Pharmaceuticals by 75.0% during the second quarter. Worth Venture Partners LLC now owns 23,627 shares of the specialty pharmaceutical company’s stock worth $56,000 after acquiring an additional 10,127 shares during the last quarter. Delek Group Ltd. grew its stake in shares of Foamix Pharmaceuticals by 23.2% during the second quarter. Delek Group Ltd. now owns 62,437 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 11,741 shares during the last quarter. Finally, Stifel Financial Corp purchased a new stake in shares of Foamix Pharmaceuticals during the third quarter worth about $54,000. Institutional investors and hedge funds own 47.29% of the company’s stock.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

See Also: Overbought

Analyst Recommendations for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

15,211 Shares in AT&T Inc.  Acquired by Beacon Financial Advisory LLC
15,211 Shares in AT&T Inc. Acquired by Beacon Financial Advisory LLC
32,625 Shares in Pfizer Inc.  Purchased by Beacon Financial Advisory LLC
32,625 Shares in Pfizer Inc. Purchased by Beacon Financial Advisory LLC
AlphaCore Capital LLC Takes Position in Chevron Co.
AlphaCore Capital LLC Takes Position in Chevron Co.
AlphaCore Capital LLC Takes Position in Pfizer Inc.
AlphaCore Capital LLC Takes Position in Pfizer Inc.
Amazon.com, Inc.  Shares Sold by Rothschild Capital Partners LLC
Amazon.com, Inc. Shares Sold by Rothschild Capital Partners LLC
Argyle Capital Management Inc. Purchases 717 Shares of Exxon Mobil Co.
Argyle Capital Management Inc. Purchases 717 Shares of Exxon Mobil Co.


© 2006-2020 Ticker Report